



"Courtemanche, Steven"
<Steven.Courtemanche@nrc.gov>

09/18/2009 11:36 AM

To "White, Duane" <Duane.White@nrc.gov>

cc "Dante.Huntsman@inl.gov" <Dante.Huntsman@inl.gov>

bcc

Subject: Additional Information for NMED 090597

History:

✉ This message has been replied to.

On September 17, 2009, you requested additional information on the above NMED Record.

(1) What corrective action(s) were taken to prevent recurrence?

The licensee will make routine use of sagittal views of an ultrasound probe. The ultrasonic technique allows for the visual confirmation of needle depth in relation to the position of the bladder and the base of the prostate gland. (Aside: Since this action is in for consideration of escalated enforcement, there may be more or different corrective actions implemented by the licensee.)

(2) What was the activity of I-125 seeds given to the patient?

Each seed contained 0.371 millicuries of activity and there were 22 seeds implanting giving a total activity of 8.162 millicuries.

(3) What was the determined dose given to the patient?

The determined dose given to the patient at the D90 isodose curve line was 26.7 Gray. The prescribed dose at the same location was 145 Gray.

(4) What was the model number of the seeds? STM-1251

(5) Who was the manufacturer of the seeds? Bard Brachytherapy, Inc.

This record should be kept open because it is being considered for escalated enforcement. I will try to get you more information if you have any additional questions and when it becomes available.